PYC Insider Trading

Insider Trading Chart
Insider Trading History
Frequently Asked Questions
About

Insider Ownership Percentage: 58.47%

Insider Buying (Last 12 Months): A$88,688.98

Insider Selling (Last 12 Months): A$0.00

PYC Therapeutics Insider Trading History Chart

PYC Therapeutics Share Price & Price History

A^$0.00

+0.30 (1.20%)

As of 01/1/2000 01:00 AM ET

Lithium Discovery So BIG You Can't Miss it, Even From Space

From Financial Alphas | Ad

With the green energy transition well underway, lithium demand is rapidly outpacing projected supply. While companies frantically search for new sources of this critical metal, one small company is sitting on a massive claim in North America - So big in fact that it can clearly be seen from space!

Free Investor Report Reveals Ambitious Plan To Mee

PYC Therapeutics Insider Trading History

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction
7/14/2023	Alan Tribe	Insider	Issued	254,545,459	A$0.06	A$14,000,000.25
7/10/2023	Rohan Hockings	Insider	Issued	18,181,818	A$0.06	A$999,999.99
6/29/2023	Alan Tribe	Insider	Buy	82,610	A$0.05	A$4,378.33
6/26/2023	Alan Tribe	Insider	Buy	1,590,767	A$0.05	A$84,310.65
8/10/2022	Alan Tribe	Insider	Buy	491,463	A$0.06	A$29,979.24
8/3/2022	Alan Tribe	Insider	Buy	1,683,537	A$0.06	A$102,695.76
6/10/2021	Rohan Hockings	Insider	Exercise	10,000,000	A$0.04	A$390,000.00
2/17/2021	Alan Tribe	Insider	Buy	600,000	A$0.14	A$81,000.00

Trading Experts Call It “The Perfect Tesla Trade”

From Wealthpress | Ad

Thanks to a new discovery linked to shares of Tesla, regular folks can now target gains of 100% or more in six days or less. New research shows it’s happened 23 different times this year. The next trade is scheduled for this Thursday.

Click here for details,

SEC Filings (Institutional Ownership Changes) for PYC Therapeutics (ASX:PYC)

PYC Therapeutics Limited, a drug-development company, engages in the discovery and development of drug solutions in the areas of RNA therapeutics in Australia. The company's preclinical development programs include VP-001, a drug program for retinitis pigmentosa type 11; PYC-001, a drug program for the treatment of autosomal dominant optic atrophy; and PYC-002 a drug program for the treatment of a severe neurodevelopmental disorder. It also focuses on the development of programs for kidney, neurodevelopmental, retinal, and central nervous system diseases. PYC Therapeutics Limited has academic-industry collaborations with Murdoch University to support drug discovery and development efforts in the field of neurodegenerative disorders. The company was formerly known as Phylogica Limited and changed its name to PYC Therapeutics Limited in November 2019. PYC Therapeutics Limited was incorporated in 2001 and is based in Nedlands, Australia.

Today's Range

Now: N/A

50 Day Range

MA: N/A

52 Week Range

Now: N/A

Volume

N/A

Average Volume

N/A

Market Capitalization

N/A

P/E Ratio

N/A

Dividend Yield

9.46%

Beta

0.57

Who are the company insiders with the largest holdings of PYC Therapeutics?: PYC Therapeutics' top insider shareholders include:
Alan Tribe (Insider)
Rohan Hockings (Insider)
Learn More about top insider investors at PYC Therapeutics.